It is known that the CV protection effect of GLP-1RAs have been proven through eight large-scale clinical studies, including Evaluation of LIXisenatide in Acute coronary syndrome (ELIXA) [66], LEADER [44], Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN)-6 [67], Exenatide Study of Cardiovascular Event Lowering (EXSCEL) [68], Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes) [69], Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) [70], Peptide Innovation for Early Diabetes Treatment (PIONEER) 6 [67,71], and AMPLITUDE-O [51]
Frequently Asked Questions Can I lose weight with GLP-1 therapy if I have only 20 to 30 pounds to lose
No reconstitution is needed for topical formulations
403 Given that vascular calcification is a cornerstone in preventing arterial stiffness, promising data suggest that the inhibition of tissue nonspecific alkaline phosphatase (TNAP) decreases cardiovascular calcification
Some pediatric metabolic conditions are treated with L-carnitine under specialist care, but self-directed use is not advised
